Clinical Course
The clinical presentation of primary PCL is more aggressive than that of multiple myeloma, and the clinical features found in PCL involves combination of those found in acute leukemia and those found in myeloma. PCL patients have a higher presenting tumor burden; higher frequencies of (involvement of organs other than the bone marrow by disease), thrombocytopenia (decreased platelet count), anemia, hypercalcemia (elevated blood calcium), and renal impairment; increased levels of serum lactate dehydrogenase (LDH) and β-2 microglobulin and plasma cell proliferative activity. The incidence of lytic bone lesions is slightly lower than that usually observed in multiple myeloma. PCL is extremely aggressive associated with short survival (median survival of 6–8 months).
Read more about this topic: Plasma Cell Leukemia